Trial
NCT03666988
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Neoplasms
Intervention
GSK3368715
Why stopped
Overall benefit-risk profile did not support continuation of the study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-20